BeiGene, Ltd. Banner Image

BeiGene, Ltd. has reached its limit for free report views

Work for BeiGene, Ltd.? Upgrade Your Profile and unlock all your annual reports.

BeiGene, Ltd.

  • Ticker BGNE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BeiGene, Ltd. Logo Image
  • 1001-5000 Employees
  • Based in Cambridge, Massachusetts
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Their 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeuticsMore. They currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. They also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
4.8 / 5.0 (234)

BeiGene, Ltd. reports have an aggregate usefulness score of 4.8 based on 234 reviews.

BeiGene, Ltd.

Most Recent Annual Report

BeiGene, Ltd.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. BeiGene, Ltd. has reached its limit for free report views.

Older/Archived Annual Reports

BeiGene, Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!